Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.

You may also be interested in...

Financings Of The Fortnight Ponders A Post-Euro Financing Environment

Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.

Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line

In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.

Disappointing Provenge Sales Stir Doubts About Demand

Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts